Mini Review Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.4.060
Cancer-Related Pain: Inside a New Dynamic Personalized Approach. A Narrative Review
Mariateresa Giglio1, Giustino Varrassi2, Filomena Puntillo1,3,*
- 1Anaesthesia, Intensive Care and Pain Unit, Policlinico Hospital, Bari, Italy
- 2Paolo Procacci Foundation, Italy
- 3Department of Interdisciplinary Medicine, University of Bari “Aldo Moro”, Bari, Italy
Corresponding Author
Filomena Puntillo, filomena.puntillo@uniba.it; nuccia.puntillo@gmail.com
Received Date: February 01, 2022
Accepted Date: February 18, 2022
Giglio M, Varrassi G, Puntillo F. Cancer-Related Pain: Inside a New Dynamic Personalized Approach. A Narrative Review. J Cancer Immunol. 2022;4(1):17-21.
Copyright: © 2022 Giglio M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Prognostic Role of Human Epididymis Protein 4 (HE4) in Ovarian Cancer Treatment: Our Point of View
In the last 10 years, the marker “Human Epididymis protein 4 (HE4)” for the management of gynecological tumors has entered powerfully in the world literature. At the moment, carrying out an accurate research in the main scientific portals such as PubMed, we can find more than 2,000 works concerning Cancer antigen-125 (Ca125), but those concerning HE4 are less than 400.
Botulinum Toxin: The Promising Future of Prostate Cancer Treatment
Botulinum toxin (BT) is a potent poisonous neurotoxin produced by the bacterium Clostridium botulinum and related species [1]. Its action consists of inhibiting neuromuscular junctions by blocking the release of acetylcholine and desensitizing sensory nerves.
NOXA the BCL-2 Family Member behind the Scenes in Cancer Treatment
NOXA is a critical mediator of stress responses to anticancer drugs. This BH3-only protein sets the apoptotic threshold in cancer cells in response to chemotherapies by counteracting the prosurvival BCL-2 family protein MCL-1. A complex and dynamic network relying on both highly controlled gene transcription activity and protein degradation by proteasome, regulates cellular NOXA levels from low in steady state to rapidly enhanced upon stressful condition.
Relevance of Neuropilin 1 and Neuropilin 2 Targeting for Cancer Treatment
Neuropilins (NRPs) are a class of transmembrane glycoprotein co-receptors including Neuropilin 1 (NRP1) and Neuropilin 2 (NRP2). They are the co-receptors of different families of receptors, thus they are involved in many hallmarks of cancer.
Biomarkers of Pembrolizumab Efficacy in First-Line Advanced PD-L1 ≥ 50% Non-Small Cell Lung Cancer Treatment
Lung cancer is the leading cause of cancer death worldwide. In 2020, a total of 19 million cancer patients were diagnosed, of which 11.4% were lung cancer, causing 18% of all cancer deaths. In 2020 in Spain, 29,638 cases were estimated.